TABLE 1.

Adjuvant activities associated with LT-II toxins when coadministered with RiVax and RVEc

LT-II enterotoxin	RiVax (5 μg)a				RiVax (0.5 μg)				RVEc (0.5 μg)
	GMTb (day)		% Viabc	Survivald	GMT (day)		% Viab	Survival	GMT (day)		% Viab	Survival
	17	27			17	27			17	27
LT-IIae	47,771	95,543	45f	10/10	12,800	27,437	23f	10/10	10,397	31,517	13f	10/10
LT-IIb	11,143	38,802	17	10/10	4,525	33,779	32f	10/10	7,352	29,407	39 f	10/10
LT-IIb(T13I)	5,486	44,572	20	10/10	3,430	19,401	21	10/10	6,400	19,401	20	10/10
LT-IIc	15,759	38,802	23	10/10	1,213	19,401	11	10/10	2,599	14,703	3	10/10
-	47	16,890	10	10/10	30	3,940	4	10/10	36	2,263	1	10/10

^aRicin subunit antigen and dose used in the experiment.

^bGeometric mean endpoint titer.

^cMean cell viability achieved by a 1:50 dilution of serum collected on day 27 for groups receiving 0.5 μg RiVax or RVEc or 1:100 for serum collected on day 27 from mice that received 5 μg RiVax.

^dNumber of mice to survive a 10 LD₅₀ ricin challenge on day 34 out of 10 total mice. Sham-immunized mice (not shown) all succumbed to ricin challenge, as shown in the accompanying figures.

^eAdjuvant in a given experiment at a dose of 1 μg.

^fP < 0.05 vs RiVax or RVEc without adjuvant.